Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersEmergency Medicine Physician in Los Angeles, CA
NPI: 1013946367Primary Practice Location
RONALD REAGAN UCLA MEDICAL CENTER
757 Westwood Plz, Los Angeles, CA
Primary Employer
UC Regents UCLA Emegency Medicine Physicians Group
uclahealth.org
HQ Phone
Get M.D. David's Phone Numberphone_androidMobile
Get M.D. David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
IA State Medical License
CA State Medical License
1982 - 2026
IA State Medical License
2019 - 2026
FL State Medical License
2012 - 2021
American Board of Emergency Medicine
Emergency Medicine
American Board of Internal Medicine
Internal Medicine
UCLA David Geffen School of Medicine/UCLA Medical Center
Fellowship • Infectious Disease
1987 - 1989
Residency • Internal Medicine
1981 - 1984
UCLA David Geffen School of Medicine/UCLA Medical Center/Olive View
Residency • Emergency Medicine
1984 - 1986
University of California at San Diego
B.A. • Chemistry and Biology
1974 - 1977
University of Illinois College of Medicine - Chicago
medicine.uic.edu
Medical School
Until 1981
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99285Emergency department visit, problem with significant threat to life or function | 42 | 42 |
| 2 | 99284Emergency department visit with moderate level of medical decision making | 22 | 22 |
Authors: @ValidYN, LastName, ForeName, Initials, AffiliationInfo
Journal: Ann Emerg Med
The association of antimicrobial resistance with cure and quality of life among women with acute uncomplicated cystitis.
Authors: Flora Vardanian
Lead Sponsor: University of Washington
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lead Sponsor: Olive View-UCLA Education & Research Institute
Collaborators: Centers for Disease Control and Prevention, IHMA laboratories
Intervention / Treatment: OTHER: urine culture and susceptibility testing
Lead Sponsor: University of Washington
Collaborators: Patient-Centered Outcomes Research Institute
Intervention / Treatment: DRUG: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, PROCEDURE: Appendectomy
